Coherus Reports Q4 Revenue of $12.75M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy CHRS?
Reports Q4 revenue $12.75M, consensus $14.09M. "We are pleased with our progress in 2025, having doubled LOQTORZI sales while completing the transformation from a biosimilars company to an innovative oncology company focused on overcoming immune resistance in cancer. At the same time, we continued to reduce our overall debt since its peak in 2024 by over 90% to $38.8 million," said Denny Lanfear, Coherus chairman and CEO. "We are now strategically positioned with growing revenues from our foundational PD-1 inhibitor, potential deal opportunities across the portfolio and geographies, and two promising pipeline candidates with multiple 2026 clinical readouts."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CHRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CHRS
Wall Street analysts forecast CHRS stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.950
Low
4.00
Averages
5.50
High
7.00
Current: 1.950
Low
4.00
Averages
5.50
High
7.00
About CHRS
Coherus Oncology, Inc., formerly Coherus BioSciences, Inc., is a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Coherus Oncology Q4 2025 Earnings Call Highlights
- Successful Strategic Transformation: Coherus Oncology has completed its strategic pivot to focus on innovative oncology, acquiring Surface Oncology and reducing debt from $480 million to $38.8 million, a reduction of over 90%, significantly improving its financial position.
- LOQTORZI Sales Growth: LOQTORZI's net revenue reached $40.8 million in 2025, up 113% from $19.1 million in 2024, with expectations to achieve $175 million in annual revenue by 2028, capturing a 70% market share of a $250 million addressable market.
- Significant Cost Control: The company reported SG&A expenses of $23.6 million in Q4, down from $29.6 million in the same quarter last year, demonstrating substantial operational efficiency improvements, while R&D expenses increased to $31 million.
- Optimistic Future Outlook: Management anticipates a quarter-over-quarter demand growth of 10% to 15% for LOQTORZI and plans to provide revenue guidance for 2026 in the next earnings call, reflecting confidence in future market potential.
See More
Coherus Oncology Reports Strong 2025 Financial Results
- Significant Revenue Growth: Coherus Oncology reported a net revenue of $40.8 million for 2025, a remarkable 113% increase from $19.1 million in 2024, indicating strong market acceptance of its next-gen PD-1 inhibitor, LOQTORZI, and suggesting enhanced future sales potential.
- Substantial Debt Reduction: The company successfully reduced its debt from $480 million to $38.8 million, a decrease of over 90%, significantly improving its financial position and providing greater funding flexibility for future R&D and market expansion.
- Increased R&D Spending: Despite overall cost control, Coherus raised its R&D expenses from $20.8 million to $31 million in Q4 2025, reflecting the company's commitment to new product development aimed at maintaining competitive advantage through innovation.
- Strong Cash Position: At the end of 2025, the company reported cash, cash equivalents, and investments totaling $172.1 million, ensuring financial stability for future operations and supporting potential strategic investments.
See More
Coherus BioSciences Reports Q4 Earnings Miss
- Earnings Miss: Coherus BioSciences reported a Q4 non-GAAP EPS of -$0.34, missing expectations by $0.03, indicating challenges in profitability that could undermine investor confidence.
- Revenue Growth Lag: Despite a 64.9% year-over-year revenue increase to $12.7M, the figure fell short of market expectations by $1.39M, reflecting competitive pressures that may impact future cash flows.
- Rating Downgrade: Analysts downgraded Coherus to 'Hold' due to potential advancements of the anti-CCR8 CHS-114, which may lower investor expectations for future growth and affect stock performance.
- Funding Initiative: Coherus Oncology announced a stock offering priced to raise $50.1M to support future R&D projects, a move that may dilute existing shareholders but provides essential funding for the company's growth initiatives.
See More
Coherus BioSciences to Announce Q4 Earnings on March 9
- Earnings Announcement Schedule: Coherus BioSciences is set to release its Q4 2023 earnings on March 9 after market close, with a consensus EPS estimate of -$0.31, reflecting a 10.7% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Decline Forecast: The anticipated revenue for Q4 is $14.09 million, representing a staggering 74% year-over-year decrease, which highlights major challenges in market competition and product sales that could impact investor confidence moving forward.
- Historical Performance Review: Over the past two years, Coherus has only beaten EPS estimates 13% of the time and revenue estimates 63% of the time, indicating considerable volatility in its performance, prompting investors to exercise caution in evaluating future outcomes.
- Stock Offering Update: Coherus Oncology recently announced a proposed public offering of common stock to raise $50.1 million, a move that may dilute existing shareholders while underscoring the company's urgent need for capital.
See More
Coherus Oncology to Release 2025 Financial Results on March 9, 2026
- Earnings Release Schedule: Coherus Oncology will announce its full-year and fourth-quarter 2025 financial results after market close on March 9, 2026, which may influence investor confidence.
- Conference Call Details: The management team will host a conference call at 4:30 p.m. Eastern Time on March 9 to discuss financial results and provide a business update, enhancing transparency and investor communication.
- Webcast Replay Availability: A replay of the webcast will be accessible on the company's investor website following the conclusion of the call, ensuring that investors who cannot attend can still access critical information.
- Company Strategy Overview: Coherus Oncology focuses on growing sales of its PD-1 inhibitor LOQTORZI® and advancing the development of new indications, aiming to enhance market competitiveness through innovative anti-tumor therapies.
See More
Coherus Oncology to Present at Upcoming Conferences
- Conference Schedule: Coherus Oncology will present at the 46th Annual TD Cowen Healthcare Conference in Boston on March 4, 2026, at 11:50 a.m. EDT, followed by the Citizens Life Sciences Conference in Miami on March 10, 2026, at 2:50 p.m. EDT, showcasing its latest advancements in oncology.
- Webcast Availability: All presentations will be accessible via webcast through the Investor Events Calendar section of the Coherus Oncology website, with replays available for approximately 90 days, ensuring investors can access key information and enhancing transparency.
- Product Strategy: Coherus Oncology's strategic focus is on driving sales of its PD-1 inhibitor LOQTORZI® in R/M Nasopharyngeal Carcinoma while advancing the development of new indications in combination with its pipeline candidates and partners, aiming to enhance sales multiples and synergies.
- Innovative Pipeline: The company is developing multiple antibody immunotherapy candidates, including Tagmokitug and Casdozokitug, currently in clinical trials for advanced solid tumors, demonstrating potential to enhance tumor immune responses and further solidify its market position in oncology.
See More
Coherus Oncology Q4 2025 Earnings Call Highlights
- Successful Strategic Transformation: Coherus Oncology has completed its strategic pivot to focus on innovative oncology, acquiring Surface Oncology and reducing debt from $480 million to $38.8 million, a reduction of over 90%, significantly improving its financial position.
- LOQTORZI Sales Growth: LOQTORZI's net revenue reached $40.8 million in 2025, up 113% from $19.1 million in 2024, with expectations to achieve $175 million in annual revenue by 2028, capturing a 70% market share of a $250 million addressable market.
- Significant Cost Control: The company reported SG&A expenses of $23.6 million in Q4, down from $29.6 million in the same quarter last year, demonstrating substantial operational efficiency improvements, while R&D expenses increased to $31 million.
- Optimistic Future Outlook: Management anticipates a quarter-over-quarter demand growth of 10% to 15% for LOQTORZI and plans to provide revenue guidance for 2026 in the next earnings call, reflecting confidence in future market potential.
See More
Coherus Oncology Reports Strong 2025 Financial Results
- Significant Revenue Growth: Coherus Oncology reported a net revenue of $40.8 million for 2025, a remarkable 113% increase from $19.1 million in 2024, indicating strong market acceptance of its next-gen PD-1 inhibitor, LOQTORZI, and suggesting enhanced future sales potential.
- Substantial Debt Reduction: The company successfully reduced its debt from $480 million to $38.8 million, a decrease of over 90%, significantly improving its financial position and providing greater funding flexibility for future R&D and market expansion.
- Increased R&D Spending: Despite overall cost control, Coherus raised its R&D expenses from $20.8 million to $31 million in Q4 2025, reflecting the company's commitment to new product development aimed at maintaining competitive advantage through innovation.
- Strong Cash Position: At the end of 2025, the company reported cash, cash equivalents, and investments totaling $172.1 million, ensuring financial stability for future operations and supporting potential strategic investments.
See More
Coherus BioSciences Reports Q4 Earnings Miss
- Earnings Miss: Coherus BioSciences reported a Q4 non-GAAP EPS of -$0.34, missing expectations by $0.03, indicating challenges in profitability that could undermine investor confidence.
- Revenue Growth Lag: Despite a 64.9% year-over-year revenue increase to $12.7M, the figure fell short of market expectations by $1.39M, reflecting competitive pressures that may impact future cash flows.
- Rating Downgrade: Analysts downgraded Coherus to 'Hold' due to potential advancements of the anti-CCR8 CHS-114, which may lower investor expectations for future growth and affect stock performance.
- Funding Initiative: Coherus Oncology announced a stock offering priced to raise $50.1M to support future R&D projects, a move that may dilute existing shareholders but provides essential funding for the company's growth initiatives.
See More
Coherus BioSciences to Announce Q4 Earnings on March 9
- Earnings Announcement Schedule: Coherus BioSciences is set to release its Q4 2023 earnings on March 9 after market close, with a consensus EPS estimate of -$0.31, reflecting a 10.7% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Decline Forecast: The anticipated revenue for Q4 is $14.09 million, representing a staggering 74% year-over-year decrease, which highlights major challenges in market competition and product sales that could impact investor confidence moving forward.
- Historical Performance Review: Over the past two years, Coherus has only beaten EPS estimates 13% of the time and revenue estimates 63% of the time, indicating considerable volatility in its performance, prompting investors to exercise caution in evaluating future outcomes.
- Stock Offering Update: Coherus Oncology recently announced a proposed public offering of common stock to raise $50.1 million, a move that may dilute existing shareholders while underscoring the company's urgent need for capital.
See More
Coherus Oncology to Release 2025 Financial Results on March 9, 2026
- Earnings Release Schedule: Coherus Oncology will announce its full-year and fourth-quarter 2025 financial results after market close on March 9, 2026, which may influence investor confidence.
- Conference Call Details: The management team will host a conference call at 4:30 p.m. Eastern Time on March 9 to discuss financial results and provide a business update, enhancing transparency and investor communication.
- Webcast Replay Availability: A replay of the webcast will be accessible on the company's investor website following the conclusion of the call, ensuring that investors who cannot attend can still access critical information.
- Company Strategy Overview: Coherus Oncology focuses on growing sales of its PD-1 inhibitor LOQTORZI® and advancing the development of new indications, aiming to enhance market competitiveness through innovative anti-tumor therapies.
See More
Coherus Oncology to Present at Upcoming Conferences
- Conference Schedule: Coherus Oncology will present at the 46th Annual TD Cowen Healthcare Conference in Boston on March 4, 2026, at 11:50 a.m. EDT, followed by the Citizens Life Sciences Conference in Miami on March 10, 2026, at 2:50 p.m. EDT, showcasing its latest advancements in oncology.
- Webcast Availability: All presentations will be accessible via webcast through the Investor Events Calendar section of the Coherus Oncology website, with replays available for approximately 90 days, ensuring investors can access key information and enhancing transparency.
- Product Strategy: Coherus Oncology's strategic focus is on driving sales of its PD-1 inhibitor LOQTORZI® in R/M Nasopharyngeal Carcinoma while advancing the development of new indications in combination with its pipeline candidates and partners, aiming to enhance sales multiples and synergies.
- Innovative Pipeline: The company is developing multiple antibody immunotherapy candidates, including Tagmokitug and Casdozokitug, currently in clinical trials for advanced solid tumors, demonstrating potential to enhance tumor immune responses and further solidify its market position in oncology.
See More
